EOLE: Ventilation/Perfusion PET/CT With Galligas and 68Ga-MAA for Regional Lung Function Assessment After Pulmonary Embolism

Sponsor
University Hospital, Brest (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05103670
Collaborator
(none)
32
1
1
33.1
1

Study Details

Study Description

Brief Summary

In patients with pulmonary embolism (PE), after three or six months of anticoagulation, persistent dyspnea and impairment of quality of life are observed in at least 30% of cases.

The "RAMBO" trial is a French academic, multicenter, randomized (1:1 ratio), parallel arm, controlled, that aimed to assess the efficacy of pulmonary rehabilitation (PR) on the quality of life in patients with an acute symptomatic PE treated with anticoagulant therapy during at least 3 months and who present an impairment of quality of life and/or persistent dyspnea despite anticoagulant therapy.

Ventilation/Perfusion (V/Q) PET/CT is a novel imaging modality for the assessment of regional lung function. The same carrier molecules as conventional V/Q imaging are used, but they are labeled with 68Gallium, a ß+ isotope, instead of 99mTc, allowing acquisition of images with PET technology.

The EOLE study is an ancillary pilot study of the RAMBO trial, in which patients will benefit, in addition to the extensive work up scheduled as per study protocol, from a V/Q PET/CT scan before and after PR. The aim of the study is to assess the impact of PR on regional lung function with lung V/Q PET/CT imaging.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Ventilation/Perfusion PET/CT with Galligas and 68Ga-MAA
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
32 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Intervention Model Description:
EOLE is an ancillary study which selects patients included in the RAMBO study. The RAMBO study is a 2-arm-parallel study which patients included in one arm will undergo a 3-month pulmonary rehabilitation, and the patients included in the other arm won't. The EOLE study will include patients in both arms of the RAMBO study. All participants will undergo a PET/CT scan at inclusion and at 3 months.EOLE is an ancillary study which selects patients included in the RAMBO study. The RAMBO study is a 2-arm-parallel study which patients included in one arm will undergo a 3-month pulmonary rehabilitation, and the patients included in the other arm won't. The EOLE study will include patients in both arms of the RAMBO study. All participants will undergo a PET/CT scan at inclusion and at 3 months.
Masking:
None (Open Label)
Primary Purpose:
Basic Science
Official Title:
Ventilation/Perfusion PET/CT With Galligas and 68Ga-MAA for Regional Lung Function Assessment After Pulmonary Embolism
Anticipated Study Start Date :
Dec 15, 2021
Anticipated Primary Completion Date :
Dec 16, 2021
Anticipated Study Completion Date :
Sep 16, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Patients undergoing a Ventilation/Perfusion PET/CT at inclusion and 3 months later

EOLE is an ancillary study which selects patients included in the RAMBO study. The RAMBO study is a 2-arm-parallel study which patients included in one arm will undergo a 3-month pulmonary rehabilitation, and the patients included in the other arm won't. The EOLE study will include specific patients in both arms of the RAMBO study, and all of the participants will undergo a PET/CT scan at the inclusion and 3 months later.

Procedure: Ventilation/Perfusion PET/CT with Galligas and 68Ga-MAA
32 patients will undergo a Ventilation/Perfusion PET/CT with Galligas and 68Ga-MAA at the inclusion and 3 months later.

Outcome Measures

Primary Outcome Measures

  1. Pulmonary vascular obstruction index (PVOI) on V/Q PET/CT imaging. [3 months]

    Expressed as a percentage of whole lung

Secondary Outcome Measures

  1. Pulmonary ventilation impairment index on V/Q PET/CT imaging. [3 months]

    Expressed as a percentage of whole lung

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 99 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patient included in the RAMBO study, whose inclusion criteria are: Age ≥ 18 years; Patient treated with at least 3 months and up to 8 months of anticoagulation for an acute symptomatic PE diagnosed according the ESC and ACCP guidelines; Patients who have a PembQol score ≥ 10% and whose total scores for the subgroups Q1 (dyspnea) and Q4 (impact of daily life) are ≥ 10%.

  • Patients planned to be randomized

  • Abnormal conventional V/Q scan at V1

  • Give consent to participate to the EOLE study

Exclusion Criteria:
  • Non inclusion criteria of the RAMBO trial:

  • Previsible inability to perform the effort test and/or PR

  • Presence of CTEPH according to international guidelines

  • Patients treated for acute PE with anticoagulants for more than 8 months

  • Active cancer or in remission for less than two years

  • Dyspnea post - COVID due to parenchymal injuries

  • Post-COVID hyperventilation syndrome without pulmonary vascular perfusion sequelae

  • Physical or psychological inability to undertake PR

  • Isolated or more distal segmental PE

  • Neuro-muscular disease with PR contraindication.

  • Cardiac insufficiency (unstable coronary artery disease)

  • Severe respiratory failure (long-term oxygen therapy, pulmonary hypertension)

  • Chronic dyspnea MMRC ≥ 2 before PE

  • Cardiac or respiratory rehabilitation in the previous year

  • Indication to urgent PR within 6 months at the time of inclusion

  • Life expectancy of less than 12 months

  • Inability to give consent

  • Patient under guardianship or curatorship

  • Patient deprived of liberty by an administrative or judicial decision

  • Patient has not social security affiliation or who don't beneficiary of such social security

After initial PR work up, patients with following criteria cannot be included:
  • Incapacity to perform the effort test

  • Effort test stopped because of hemodynamic intolerance

  • Cardiac failure discovered after PR work up

Contacts and Locations

Locations

Site City State Country Postal Code
1 LEROUX Pierre-Yves Brest France 29200

Sponsors and Collaborators

  • University Hospital, Brest

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University Hospital, Brest
ClinicalTrials.gov Identifier:
NCT05103670
Other Study ID Numbers:
  • 29BRC21.0139 (EOLE)
First Posted:
Nov 2, 2021
Last Update Posted:
Nov 2, 2021
Last Verified:
Oct 1, 2021
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by University Hospital, Brest
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 2, 2021